Bexarotene is a new treatment option for lymphomatoid papulosis.

Abstract

BACKGROUND:

Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.

OBJECTIVE:

To determine whether bexarotene is effective in treating LyP.

METHODS:

Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene.

RESULTS:

A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients.

CONCLUSIONS:

Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.

• Authors: Richard A Krathen, Staci Ward, Madeleine Duvic
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 206 Issue 2 Pg. 142-7 ( 2003) ISSN: 1018-8665 [Print] Switzerland
• PMID: 12592082 (Publication Type: Case Reports, Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Anticarcinogenic Agents
• Tetrahydronaphthalenes
• Bexarotene

Topics

• Administration, Oral
• Administration, Topical
• Adult
• Aged
• Anticarcinogenic Agents (administration & dosage)
• Bexarotene
• Female
• Humans
• Lymphomatoid Papulosis (drug therapy)
• Male
• Middle Aged
• Palliative Care
• Prospective Studies
• Tetrahydronaphthalenes (administration & dosage)